- Home
- PKST vs TRML Comparison
PKST vs TRML Comparison
Compare PKST & TRML Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PKST
- TRML
- Stock Information
- Founded
- PKST 2008
- TRML 2021
- Country
- PKST United States
- TRML United States
- Employees
- PKST N/A
- TRML N/A
- Industry
- PKST Real Estate Investment Trusts
- TRML Biotechnology: Pharmaceutical Preparations
- Sector
- PKST Real Estate
- TRML Health Care
- Exchange
- PKST Nasdaq
- TRML Nasdaq
- Market Cap
- PKST 477.3M
- TRML 419.1M
- IPO Year
- PKST N/A
- TRML N/A
- Fundamental
- Price
- PKST $11.73
- TRML $20.65
- Analyst Decision
- PKST Hold
- TRML Strong Buy
- Analyst Count
- PKST 1
- TRML 6
- Target Price
- PKST $15.00
- TRML $54.00
- AVG Volume (30 Days)
- PKST 230.3K
- TRML 215.8K
- Earning Date
- PKST 10-30-2024
- TRML 11-07-2024
- Dividend Yield
- PKST 7.91%
- TRML N/A
- EPS Growth
- PKST N/A
- TRML N/A
- EPS
- PKST N/A
- TRML N/A
- Revenue
- PKST $233,198,000.00
- TRML N/A
- Revenue This Year
- PKST N/A
- TRML N/A
- Revenue Next Year
- PKST $7.98
- TRML N/A
- P/E Ratio
- PKST N/A
- TRML N/A
- Revenue Growth
- PKST 11.21
- TRML N/A
- 52 Week Low
- PKST $9.89
- TRML $12.12
- 52 Week High
- PKST $21.73
- TRML $48.31
- Technical
- Relative Strength Index (RSI)
- PKST 36.86
- TRML 36.34
- Support Level
- PKST $11.92
- TRML $19.14
- Resistance Level
- PKST $13.41
- TRML $22.80
- Average True Range (ATR)
- PKST 0.72
- TRML 1.72
- MACD
- PKST -0.13
- TRML -0.42
- Stochastic Oscillator
- PKST 17.98
- TRML 20.71
About PKST Peakstone Realty Trust
Peakstone Realty Trust is an internally managed, publicly registered real estate investment trust (REIT) that owns and operates predominately single-tenant industrial and office properties with creditworthy tenants and long-term leases. Peakstone's portfolio consists of newer vintage, and well-located real estate assets totaling approximately 19 million square feet across 24 states in majorly high-growth coastal and sunbelt markets.
About TRML Tourmaline Bio Inc.
Tourmaline Bio Inc is a late-stage clinical biotechnology company driven by its mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune diseases. Its initial product candidate is TOUR006, a fully human monoclonal antibody that selectively binds to interleukin-6 (IL-6), a key proinflammatory cytokine involved in the pathogenesis of many autoimmune and inflammatory disorders. The anti-IL-6 and anti-IL-6 receptor (IL-6R) antibody class (IL-6 class) has over two decades of clinical and commercial experience treating over a million patients with a variety of autoimmune and inflammatory diseases.